The tweet was deleted by the author.
But we saved everything 🙂.
Invivyd has released its financial results for the third quarter 2026, alongside an update on recent business activities.
The company made the announcement through an official update, but further details on performance metrics or development specifics were not disclosed in the tweet.
View post on X Loading...
Earlier this year, Invivyd introduced VMS063, a new monoclonal antibody candidate for measles treatment and prevention at IDWeek 2026. The company has been focused on developing therapies addressing infectious diseases. Previous updates provided details on product pipelines, but recent disclosures remain limited.